ES2394962T3 - Método de diagnóstico de enfermedades inflamatorias usando calgranulina C - Google Patents

Método de diagnóstico de enfermedades inflamatorias usando calgranulina C Download PDF

Info

Publication number
ES2394962T3
ES2394962T3 ES03708103T ES03708103T ES2394962T3 ES 2394962 T3 ES2394962 T3 ES 2394962T3 ES 03708103 T ES03708103 T ES 03708103T ES 03708103 T ES03708103 T ES 03708103T ES 2394962 T3 ES2394962 T3 ES 2394962T3
Authority
ES
Spain
Prior art keywords
calgranulin
disease
patients
serum
arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03708103T
Other languages
English (en)
Spanish (es)
Inventor
Clemens Sorg
Johannes Roth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Münster
Original Assignee
University of Münster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Münster filed Critical University of Münster
Application granted granted Critical
Publication of ES2394962T3 publication Critical patent/ES2394962T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES03708103T 2002-02-15 2003-02-17 Método de diagnóstico de enfermedades inflamatorias usando calgranulina C Expired - Lifetime ES2394962T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77600 1993-06-15
US10/077,600 US20030175713A1 (en) 2002-02-15 2002-02-15 Method for diagnosis of inflammatory diseases using CALGRANULIN C
PCT/EP2003/001575 WO2003069341A2 (en) 2002-02-15 2003-02-17 Method of diagnosis of inflammatory diseases using calgranulin c

Publications (1)

Publication Number Publication Date
ES2394962T3 true ES2394962T3 (es) 2013-02-07

Family

ID=27732684

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03708103T Expired - Lifetime ES2394962T3 (es) 2002-02-15 2003-02-17 Método de diagnóstico de enfermedades inflamatorias usando calgranulina C

Country Status (8)

Country Link
US (3) US20030175713A1 (cg-RX-API-DMAC7.html)
EP (1) EP1474689B1 (cg-RX-API-DMAC7.html)
JP (2) JP5487404B2 (cg-RX-API-DMAC7.html)
AU (1) AU2003212245A1 (cg-RX-API-DMAC7.html)
CA (1) CA2474890A1 (cg-RX-API-DMAC7.html)
DK (1) DK1474689T3 (cg-RX-API-DMAC7.html)
ES (1) ES2394962T3 (cg-RX-API-DMAC7.html)
WO (1) WO2003069341A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
US20030175713A1 (en) * 2002-02-15 2003-09-18 Clemens Sorg Method for diagnosis of inflammatory diseases using CALGRANULIN C
JP2006511790A (ja) * 2002-11-14 2006-04-06 サイファージェン バイオシステムズ インコーポレイテッド 羊膜内炎症のためのバイオマーカー
WO2005064307A2 (en) 2003-12-23 2005-07-14 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6
JP4868378B2 (ja) * 2004-11-19 2012-02-01 株式会社明治 炎症性腸疾患治療薬
ES2347485T3 (es) * 2006-05-19 2010-10-29 F. Hoffmann-La Roche Ag Uso de la proteina s100a12, como marcador para el cancer colorrectal.
DE102007036678B4 (de) * 2007-08-03 2015-05-21 Sirs-Lab Gmbh Verwendung von Polynukleotiden zur Erfassung von Genaktivitäten für die Unterscheidung zwischen lokaler und systemischer Infektion
US20110184712A1 (en) * 2007-10-11 2011-07-28 Cardiodx, Inc. Predictive models and methods for diagnosing and assessing coronary artery disease
EP2210102A2 (en) * 2007-10-19 2010-07-28 Erac As Edta resistant s100a12 complexes (erac)
GB0922006D0 (en) * 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
WO2011146479A1 (en) * 2010-05-18 2011-11-24 The Texas A&M University System Method and composition for the diagnosis and monitoring of inflammatory diseases
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
CA2838284C (en) * 2011-06-04 2017-10-24 Rochester General Hospital Research Institute Methods relating to s100a12 for diagnosing infectious diseases and kit therefor
WO2013167727A2 (en) 2012-05-11 2013-11-14 Westfaelische Wilhelms-Universitaet Muenster Method for determining arthritis relapse risk
US11267854B2 (en) 2016-07-20 2022-03-08 Westfaelische Wilhelms-Universitaet Muenster Complex-specific standardization of immunological methods for the quantification of S100A12
US11287396B2 (en) 2020-06-05 2022-03-29 Princeton Biochemicals, Inc. Method and system for simultaneous determination of multiple measurable biomarkers during the development of a communicable disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455160A (en) * 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
JPH08238090A (ja) * 1995-03-06 1996-09-17 Jiro Hitomi 新規カルシウム結合タンパク
JPH08238091A (ja) * 1995-03-06 1996-09-17 Jiro Hitomi 新規カルシウム結合タンパク
EP0731166A3 (en) * 1995-03-06 1997-12-29 Tonen Corporation Novel calcium-binding proteins
US5976832A (en) * 1995-03-06 1999-11-02 Tonen Corporation DNA encoding novel calcium-binding proteins
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US6028060A (en) * 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
AU765719B2 (en) * 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
US7011952B2 (en) * 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
AU2001259710A1 (en) * 2000-05-09 2001-11-20 Genetics Institute, Llc Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
WO2002033377A2 (en) * 2000-09-20 2002-04-25 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
WO2002048310A2 (en) * 2000-12-15 2002-06-20 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
US20030175713A1 (en) * 2002-02-15 2003-09-18 Clemens Sorg Method for diagnosis of inflammatory diseases using CALGRANULIN C

Also Published As

Publication number Publication date
US20170138931A9 (en) 2017-05-18
AU2003212245A1 (en) 2003-09-04
WO2003069341A2 (en) 2003-08-21
EP1474689B1 (en) 2012-09-12
DK1474689T3 (da) 2012-12-03
JP5650985B2 (ja) 2015-01-07
EP1474689A2 (en) 2004-11-10
WO2003069341A3 (en) 2004-02-05
JP2011053222A (ja) 2011-03-17
AU2003212245A8 (en) 2003-09-04
JP5487404B2 (ja) 2014-05-07
US20050147972A1 (en) 2005-07-07
US20100311758A1 (en) 2010-12-09
CA2474890A1 (en) 2003-08-21
JP2005517414A (ja) 2005-06-16
US20030175713A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
JP5650985B2 (ja) カルグラヌリンcを用いた炎症性疾患の診断方法
Kane et al. Increased perivascular synovial membrane expression of myeloid‐related proteins in psoriatic arthritis
ES2386966T3 (es) Método para diagnosticar enfermedades infecciosas midiendo el nivel de TREM-1 soluble en una muestra
US11041864B2 (en) Method for prediction of prognosis of sepsis
US9541560B2 (en) Serological markers of inflammatory bowel disease phenotype and disease progression
Jereb et al. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia
ES2369798T3 (es) Procedimiento de diagnóstico de una enfermedad que implica un anticuerpo antireceptor at1.
ES2899007T3 (es) Métodos para predecir el riesgo de insuficiencia respiratoria en un paciente séptico al medir niveles reducidos de endocan en sangre
US20140120174A1 (en) Methods of prognosis and diagnosis of sepsis
ES2388082T3 (es) Procedimiento para el diagnóstico de una enfermedad que implica un anticuerpo antirreceptor de la endotelina
WO2003069349A2 (en) Method for diagnosis of inflammatory diseases using mrp8/mrp14
US9506923B2 (en) Method of diagnosing surgical site infections
JP7271442B2 (ja) 腎機能を診断またはモニターする方法、または腎機能障害を診断することを補助する方法
JP6158825B2 (ja) テネイシンcおよび関節リウマチにおけるその使用
Bañuelos-Andrío et al. Usefulness of analytical parameters in the management of pediatric patients with suspicion of acute pyelonephritis. Is procalcitonin reliable?
KR102705469B1 (ko) 불응성 가와사키병의 감별 진단을 위한 정보 제공 방법
Tasabehji et al. Usefulness of procalcitonin and some inflammatory parameters in septic patients
Kadhim et al. Therapeutic drug monitoring of adalimumab for dose optimization during maintenance therapy in patients with ulcerative colitis: real-world data
KR102494928B1 (ko) Mrgprx2를 이용한 즉시형 과민 반응 환자를 판별하는 방법
Sweilam et al. Study the role of serum cartilage oligomericmatrix protein (COMP) in the diagnosis of rheumatoid arthritis patients
JP5010220B2 (ja) 造血幹細胞移植療法の施行患者の病態把握方法
JP3220129B2 (ja) 流早産の可能性の判定方法及びそのための試薬
Siahanidou et al. Research Article Clinical Value of Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Levels in Term Neonates with Infection or Sepsis: A Prospective Study
Zastrzeżyńska Effect of biological treatment with omalizumab on airway remodeling and clinical parameters in patients with severe allergic asthma
Prajwal et al. Study of Clinical Profile of Community-acquired Pneumonia with Special Reference to C-reactive Protein and Procalcitonin Levels